{"name":"Amgen","slug":"amgen","ticker":"AMGN","exchange":"NASDAQ","domain":"amgen.com","description":"Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name \"AMGen\" is a portmanteau of the company's original name, Applied Molecular Genetics.","hq":"Thousand Oaks, CA","founded":0,"employees":"31500","ceo":"Robert A. Bradway","sector":"Large Biotech","stockPrice":346.57,"stockChange":6.57,"stockChangePercent":1.93,"marketCap":"$186.8B","metrics":{"revenue":25424000000,"revenueGrowth":8.6,"grossMargin":70.8,"rdSpend":0,"netIncome":7711000000,"cash":9128999936,"dividendYield":2.96,"peRatio":24.3,"fiscalYear":"FY2020"},"revenueBreakdown":[{"name":"Prolia","genericName":"DENOSUMAB","slug":"denosumab","revenue":6100000000,"yoyGrowth":0,"percentOfTotal":36.6},{"name":"Otezla","genericName":"APREMILAST","slug":"apremilast","revenue":2100000000,"yoyGrowth":0,"percentOfTotal":12.6},{"name":"Nplate","genericName":"ROMIPLOSTIM","slug":"romiplostim","revenue":1524000000,"yoyGrowth":0,"percentOfTotal":9.1},{"name":"Neupogen","genericName":"Filgrastim-Aafi","slug":"nivestym","revenue":1434000000,"yoyGrowth":0,"percentOfTotal":8.6},{"name":"Kyprolis","genericName":"carfilzomib","slug":"carfilzomib","revenue":1300000000,"yoyGrowth":0,"percentOfTotal":7.8},{"name":"Neulasta","genericName":"Pegfilgrastim-Apgf","slug":"nyvepria","revenue":1200000000,"yoyGrowth":0,"percentOfTotal":7.2},{"name":"Blincyto","genericName":"blinatumomab","slug":"blinatumomab","revenue":1000000000,"yoyGrowth":0,"percentOfTotal":6},{"name":"Aimovig","genericName":"ERENUMAB","slug":"erenumab","revenue":500000000,"yoyGrowth":0,"percentOfTotal":3},{"name":"Epogen","genericName":"Epoetin Alfa-Epbx","slug":"retacrit","revenue":400000000,"yoyGrowth":0,"percentOfTotal":2.4},{"name":"Aranesp","genericName":"DARBEPOETIN ALFA","slug":"darbepoetin-alfa","revenue":400000000,"yoyGrowth":0,"percentOfTotal":2.4},{"name":"Epogen","genericName":"EPOETIN ALFA","slug":"epoetin-alfa","revenue":400000000,"yoyGrowth":0,"percentOfTotal":2.4},{"name":"Lumakras","genericName":"SOTORASIB","slug":"sotorasib","revenue":300000000,"yoyGrowth":0,"percentOfTotal":1.8}],"timeline":[{"date":"1989-01-01","label":"Epogen first approved","drug":"Epogen","drugSlug":"retacrit","type":"approval","sentiment":"positive"},{"date":"1989-01-01","label":"Epogen first approved","drug":"Epogen","drugSlug":"epoetin-alfa","type":"approval","sentiment":"positive"},{"date":"1991-01-01","label":"Neupogen first approved","drug":"Neupogen","drugSlug":"nivestym","type":"approval","sentiment":"positive"},{"date":"2001-01-01","label":"Aranesp first approved","drug":"Aranesp","drugSlug":"darbepoetin-alfa","type":"approval","sentiment":"positive"},{"date":"2002-01-01","label":"Neulasta first approved","drug":"Neulasta","drugSlug":"nyvepria","type":"approval","sentiment":"positive"},{"date":"2004-01-01","label":"Sensipar first approved","drug":"Sensipar","drugSlug":"cinacalcet","type":"approval","sentiment":"positive"},{"date":"2008-01-01","label":"Nplate first approved","drug":"Nplate","drugSlug":"romiplostim","type":"approval","sentiment":"positive"},{"date":"2010-01-01","label":"Prolia first approved","drug":"Prolia","drugSlug":"denosumab","type":"approval","sentiment":"positive"},{"date":"2012-01-01","label":"Kyprolis first approved","drug":"Kyprolis","drugSlug":"carfilzomib","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Otezla first approved","drug":"Otezla","drugSlug":"apremilast","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Blincyto first approved","drug":"Blincyto","drugSlug":"blinatumomab","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Corlanor first approved","drug":"Corlanor","drugSlug":"ivabradine","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Imlygic first approved","drug":"Imlygic","drugSlug":"talimogene-laherparepvec","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Aimovig first approved","drug":"Aimovig","drugSlug":"erenumab","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Lumakras first approved","drug":"Lumakras","drugSlug":"sotorasib","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Imdelltra (Amg757) first approved","drug":"Imdelltra (Amg757)","drugSlug":"tarlatamab","type":"approval","sentiment":"positive"},{"date":"2026-05-30","label":"Lumakras PHASE1,PHASE2 readout","drug":"Lumakras","drugSlug":"sotorasib","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-06-07","label":"RIABNI Phase 3 readout (Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia)","drug":"RIABNI","drugSlug":"rituximab-arrx","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-06-30","label":"RIABNI Phase 3 readout (Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia)","drug":"RIABNI","drugSlug":"rituximab-arrx","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-09","label":"RIABNI Phase 3 readout (Anemia, Chronic Lymphocytic Leukemia)","drug":"RIABNI","drugSlug":"rituximab-arrx","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-31","label":"RIABNI Phase 3 readout (Primary Mediastinal Large B-Cell Lymphoma)","drug":"RIABNI","drugSlug":"rituximab-arrx","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-03-01","label":"RIABNI Phase 2 readout (Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma)","drug":"RIABNI","drugSlug":"rituximab-arrx","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-03-31","label":"AVSOLA Phase 2 readout (Crohn Disease)","drug":"AVSOLA","drugSlug":"infliximab-axxq","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-08-25","label":"Evenity Phase 3 readout (Osteogenesis Imperfecta)","drug":"Evenity","drugSlug":"romosozumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-08-25","label":"EVENITY Phase 3 readout (Osteogenesis Imperfecta)","drug":"EVENITY","drugSlug":"romosozumab-aqqg","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-09-24","label":"RIABNI Phase 2 readout (DLBCL, Diffuse Large B-Cell Lymphoma)","drug":"RIABNI","drugSlug":"rituximab-arrx","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-01","label":"RIABNI Phase 3 readout (Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma)","drug":"RIABNI","drugSlug":"rituximab-arrx","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-01","label":"RIABNI Phase 3 readout (Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma)","drug":"RIABNI","drugSlug":"rituximab-arrx","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-12-30","label":"Imdelltra (Amg757) PHASE2 readout","drug":"Imdelltra (Amg757)","drugSlug":"tarlatamab","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-03-26","label":"Imdelltra (Amg757) PHASE3 readout","drug":"Imdelltra (Amg757)","drugSlug":"tarlatamab","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-05-21","label":"Evenity Phase 3 readout (Osteogenesis Imperfecta)","drug":"Evenity","drugSlug":"romosozumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-05-21","label":"EVENITY Phase 3 readout (Osteogenesis Imperfecta)","drug":"EVENITY","drugSlug":"romosozumab-aqqg","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-08-16","label":"Otezla patent expiry (Compound)","drug":"Otezla","drugSlug":"apremilast","type":"patent_expiry","sentiment":"negative"},{"date":"2029-04-01","label":"Evenity Phase 3 readout (FHA (Functional Hypothalamic Amenorrhea))","drug":"Evenity","drugSlug":"romosozumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-04-01","label":"EVENITY Phase 3 readout (FHA (Functional Hypothalamic Amenorrhea))","drug":"EVENITY","drugSlug":"romosozumab-aqqg","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-07-15","label":"IMDELLTRA Phase 3 readout (Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer)","drug":"IMDELLTRA","drugSlug":"tarlatamab-dlle","type":"phase3_readout","sentiment":"neutral"},{"date":"2031-03-17","label":"RIABNI Phase 3 readout (Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma)","drug":"RIABNI","drugSlug":"rituximab-arrx","type":"phase3_readout","sentiment":"neutral"},{"date":"2032-03-29","label":"RIABNI Phase 3 readout (Diffuse Large B-Cell Lymphoma)","drug":"RIABNI","drugSlug":"rituximab-arrx","type":"phase3_readout","sentiment":"neutral"},{"date":"2032-03-31","label":"RIABNI Phase 3 readout (Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features)","drug":"RIABNI","drugSlug":"rituximab-arrx","type":"phase3_readout","sentiment":"neutral"},{"date":"2034-05-29","label":"Otezla patent expiry (Method of Use)","drug":"Otezla","drugSlug":"apremilast","type":"patent_expiry","sentiment":"negative"},{"date":"2034-11-29","label":"Otezla patent expiry (Compound)","drug":"Otezla","drugSlug":"apremilast","type":"patent_expiry","sentiment":"negative"},{"date":"2034-11-29","label":"Otezla patent expiry (Compound)","drug":"Otezla","drugSlug":"apremilast","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Enbrel patent cliff ($4.5B at risk)","drug":"Enbrel","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Erenumab patent cliff ($1.5B at risk)","drug":"Erenumab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":6100000000,"percentOfTotal":36.6,"drugCount":83,"colorKey":"oncology","drugs":[{"name":"Prolia","genericName":"DENOSUMAB","slug":"denosumab","indication":"Drug-induced osteoporosis","status":"marketed","revenue":6100000000},{"name":"AB248","genericName":"AB248","slug":"ab248","indication":"Other","status":"phase_1"},{"name":"AMG334","genericName":"AMG334","slug":"amg334","indication":"Other","status":"marketed"},{"name":"CCX354-C","genericName":"CCX354-C","slug":"ccx354-c","indication":"Treatment of Still's disease","status":"phase_2"},{"name":"Etanerept","genericName":"Etanerept","slug":"etanerept","indication":"Other","status":"marketed"},{"name":"Evenity","genericName":"romosozumab","slug":"romosozumab","indication":"Postmenopausal osteoporosis","status":"marketed"},{"name":"ABP 501-HCF","genericName":"ABP 501-HCF","slug":"abp-501-hcf","indication":"Other","status":"phase_1"},{"name":"ABP 501-LCF","genericName":"ABP 501-LCF","slug":"abp-501-lcf","indication":"Other","status":"phase_1"},{"name":"AGM 719","genericName":"AGM 719","slug":"agm-719","indication":"Other","status":"phase_2"},{"name":"AMG 073","genericName":"AMG 073","slug":"amg-073","indication":"Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis","status":"marketed"},{"name":"AMG 133","genericName":"AMG 133","slug":"amg-133","indication":"Other","status":"phase_1"},{"name":"AMG 162 - Prolia","genericName":"AMG 162 - Prolia","slug":"amg-162-prolia","indication":"Treatment of osteoporosis in postmenopausal women","status":"phase_2"},{"name":"AMG 172","genericName":"AMG 172","slug":"amg-172","indication":"Other","status":"phase_1"},{"name":"AMG 256","genericName":"AMG 256","slug":"amg-256","indication":"Other","status":"phase_1"},{"name":"AMG 282","genericName":"AMG 282","slug":"amg-282","indication":"Other","status":"phase_1"},{"name":"AMG 305","genericName":"AMG 305","slug":"amg-305","indication":"Other","status":"phase_1"},{"name":"AMG 355","genericName":"AMG 355","slug":"amg-355","indication":"Other","status":"phase_1"},{"name":"AMG 403","genericName":"AMG 403","slug":"amg-403","indication":"Other","status":"phase_1"},{"name":"AMG 436","genericName":"AMG 436","slug":"amg-436","indication":"Other","status":"phase_1"},{"name":"AMG 509","genericName":"AMG 509","slug":"amg-509","indication":"Other","status":"phase_1"},{"name":"AMG 513","genericName":"AMG 513","slug":"amg-513","indication":"Other","status":"phase_1"},{"name":"AMG 529","genericName":"AMG 529","slug":"amg-529","indication":"Other","status":"phase_1"},{"name":"AMG 570","genericName":"AMG 570","slug":"amg-570","indication":"Other","status":"phase_1"},{"name":"AMG 581","genericName":"AMG 581","slug":"amg-581","indication":"Other","status":"phase_1"},{"name":"AMG 592","genericName":"AMG 592","slug":"amg-592","indication":"Other","status":"phase_1"},{"name":"AMG 595","genericName":"AMG 595","slug":"amg-595","indication":"Other","status":"phase_1"},{"name":"AMG 598","genericName":"AMG 598","slug":"amg-598","indication":"Other","status":"phase_1"},{"name":"AMG 609","genericName":"AMG 609","slug":"amg-609","indication":"Other","status":"phase_1"},{"name":"AMG 623","genericName":"AMG 623","slug":"amg-623","indication":"Other","status":"phase_1"},{"name":"AMG 691","genericName":"AMG 691","slug":"amg-691","indication":"Other","status":"phase_1"},{"name":"AMG 732","genericName":"AMG 732","slug":"amg-732","indication":"Other","status":"phase_2"},{"name":"AMG 786","genericName":"AMG 786","slug":"amg-786","indication":"Other","status":"phase_1"},{"name":"AMG 890","genericName":"AMG 890","slug":"amg-890","indication":"Other","status":"phase_1"},{"name":"AMG 986","genericName":"AMG 986","slug":"amg-986","indication":"Other","status":"phase_1"},{"name":"AMG 994","genericName":"AMG 994","slug":"amg-994","indication":"Other","status":"phase_1"},{"name":"AVSOLA","genericName":"INFLIXIMAB-AXXQ","slug":"infliximab-axxq","indication":"Other","status":"marketed"},{"name":"Actonel®","genericName":"Actonel®","slug":"actonel","indication":"Other","status":"marketed"},{"name":"Aeroquin","genericName":"Aeroquin","slug":"aeroquin","indication":"Other","status":"phase_3"},{"name":"Ammonul","genericName":"Ammonul","slug":"ammonul","indication":"Other","status":"marketed"},{"name":"Antizol","genericName":"Antizol","slug":"antizol","indication":"Accidental poisoning by methyl alcohol","status":"marketed"},{"name":"Apremilast 30mg","genericName":"Apremilast 30mg","slug":"apremilast-30mg","indication":"Other","status":"marketed"},{"name":"Apremilast IR","genericName":"Apremilast IR","slug":"apremilast-ir","indication":"Other","status":"phase_1"},{"name":"Apremilast Modified Release 14","genericName":"Apremilast Modified Release 14","slug":"apremilast-modified-release-14","indication":"Other","status":"phase_1"},{"name":"Apremilast Modified Release 4","genericName":"Apremilast Modified Release 4","slug":"apremilast-modified-release-4","indication":"Other","status":"phase_1"},{"name":"Apremilast Modified Release 8","genericName":"Apremilast Modified Release 8","slug":"apremilast-modified-release-8","indication":"Other","status":"phase_1"},{"name":"Apremilast Modified Release 9","genericName":"Apremilast Modified Release 9","slug":"apremilast-modified-release-9","indication":"Other","status":"phase_1"},{"name":"Arm 1- Dose Expansion","genericName":"Arm 1- Dose Expansion","slug":"arm-1-dose-expansion","indication":"Other","status":"phase_1"},{"name":"BKEMV","genericName":"ECULIZUMAB-AEEB","slug":"eculizumab-aeeb","indication":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"marketed"},{"name":"Buphenyl (NaPBA)","genericName":"Buphenyl (NaPBA)","slug":"buphenyl-napba","indication":"Urea cycle disorders (hyperammonemia management)","status":"phase_3"},{"name":"CC-10004","genericName":"CC-10004","slug":"cc-10004","indication":"Other","status":"phase_2"},{"name":"CC10004","genericName":"CC10004","slug":"cc10004","indication":"Other","status":"phase_2"},{"name":"CCX282-B","genericName":"CCX282-B","slug":"ccx282-b","indication":"Other","status":"phase_2"},{"name":"Carboplatin, pemetrexed, docetaxel, paclitaxel","genericName":"Carboplatin, pemetrexed, docetaxel, paclitaxel","slug":"carboplatin-pemetrexed-docetaxel-paclitaxel","indication":"Other","status":"phase_1"},{"name":"Cysteamine Bitartrate Delayed-release Capsules","genericName":"Cysteamine Bitartrate Delayed-release Capsules","slug":"cysteamine-bitartrate-delayed-release-capsules","indication":"Cystinosis (nephropathic cystinosis)","status":"phase_3"},{"name":"DMARD Therapy","genericName":"DMARD Therapy","slug":"dmard-therapy","indication":"Other","status":"marketed"},{"name":"EVENITY","genericName":"ROMOSOZUMAB-AQQG","slug":"romosozumab-aqqg","indication":"Postmenopausal osteoporosis","status":"marketed"},{"name":"Erenumab 140 mg","genericName":"Erenumab 140 mg","slug":"erenumab-140-mg","indication":"Other","status":"marketed"},{"name":"Erenumab 70 mg","genericName":"Erenumab 70 mg","slug":"erenumab-70-mg","indication":"Other","status":"marketed"},{"name":"HPN-100","genericName":"HPN-100","slug":"hpn-100","indication":"Other","status":"marketed"},{"name":"IMDELLTRA","genericName":"TARLATAMAB-DLLE","slug":"tarlatamab-dlle","indication":"Other","status":"marketed"},{"name":"Imdelltra (Amg757)","genericName":"TARLATAMAB","slug":"tarlatamab","indication":"ES-SCLC with disease progression","status":"marketed"},{"name":"NaPBA","genericName":"NaPBA","slug":"napba","indication":"Urea cycle disorders (hyperammonemia management)","status":"marketed"},{"name":"PAVBLU","genericName":"AFLIBERCEPT-AYYH","slug":"aflibercept-ayyh","indication":"Other","status":"marketed"},{"name":"Pegloticase with MTX","genericName":"Pegloticase with MTX","slug":"pegloticase-with-mtx","indication":"Chronic gout refractory to conventional urate-lowering therapy","status":"marketed"},{"name":"Pembrolizumab (US)","genericName":"Pembrolizumab (US)","slug":"pembrolizumab-us","indication":"Other","status":"phase_3"},{"name":"Placebo for methotrexate","genericName":"Placebo for methotrexate","slug":"placebo-for-methotrexate","indication":"Control arm in Phase 3 clinical trial for methotrexate","status":"phase_3"},{"name":"Placebo for risendronate","genericName":"Placebo for risendronate","slug":"placebo-for-risendronate","indication":"Treatment of osteoporosis","status":"phase_3"},{"name":"Placebo to Alendronate","genericName":"Placebo to Alendronate","slug":"placebo-to-alendronate","indication":"Treatment of osteoporosis in postmenopausal women and men","status":"phase_3"},{"name":"Placebo to Romosozumab","genericName":"Placebo to Romosozumab","slug":"placebo-to-romosozumab","indication":"Postmenopausal osteoporosis in women at high risk of fracture","status":"phase_3"},{"name":"RIABNI","genericName":"RITUXIMAB-ARRX","slug":"rituximab-arrx","indication":"Other","status":"marketed"},{"name":"Romozosumab","genericName":"Romozosumab","slug":"romozosumab","indication":"Other","status":"phase_3"},{"name":"Routine Lipid Management","genericName":"Routine Lipid Management","slug":"routine-lipid-management","indication":"Other","status":"marketed"},{"name":"Sensipar®","genericName":"Sensipar®","slug":"sensipar","indication":"Other","status":"marketed"},{"name":"Standard Gout Flare Prophylaxis","genericName":"Standard Gout Flare Prophylaxis","slug":"standard-gout-flare-prophylaxis","indication":"Other","status":"marketed"},{"name":"Traditional Vitamin D Therapy","genericName":"Traditional Vitamin D Therapy","slug":"traditional-vitamin-d-therapy","indication":"Vitamin D deficiency","status":"marketed"},{"name":"UPLIZNA","genericName":"UPLIZNA","slug":"uplizna","indication":"Generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) antibody positive","status":"marketed"},{"name":"Vincrisitne","genericName":"Vincrisitne","slug":"vincrisitne","indication":"Other","status":"phase_3"},{"name":"Xaluritamig","genericName":"Xaluritamig","slug":"xaluritamig","indication":"Other","status":"phase_3"},{"name":"[14C]CCX168","genericName":"[14C]CCX168","slug":"14c-ccx168","indication":"Other","status":"phase_1"},{"name":"bisphosphonate","genericName":"bisphosphonate","slug":"bisphosphonate","indication":"Other","status":"marketed"},{"name":"gout flare prophylaxis regimen","genericName":"gout flare prophylaxis regimen","slug":"gout-flare-prophylaxis-regimen","indication":"Other","status":"marketed"},{"name":"interferon γ-1b","genericName":"interferon γ-1b","slug":"interferon-1b","indication":"Chronic granulomatous disease (CGD)","status":"phase_3"},{"name":"romosozumab HCP administration with PFS","genericName":"romosozumab HCP administration with PFS","slug":"romosozumab-hcp-administration-with-pfs","indication":"Treatment of osteoporosis in postmenopausal women at high risk of fracture","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":4034000000,"percentOfTotal":24.2,"drugCount":47,"colorKey":"neuroscience","drugs":[{"name":"Neupogen","genericName":"Filgrastim-Aafi","slug":"nivestym","indication":"Chemotherapy-induced neutropenia","status":"marketed","revenue":1434000000},{"name":"Kyprolis","genericName":"carfilzomib","slug":"carfilzomib","indication":"Multiple myeloma","status":"marketed","revenue":1300000000},{"name":"Blincyto","genericName":"blinatumomab","slug":"blinatumomab","indication":"Pre B-cell acute lymphoblastic leukemia","status":"marketed","revenue":1000000000},{"name":"Lumakras","genericName":"SOTORASIB","slug":"sotorasib","indication":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","status":"marketed","revenue":300000000},{"name":"ABP 798","genericName":"ABP 798","slug":"abp-798","indication":"Metastatic melanoma (PMEL-positive)","status":"phase_3"},{"name":"FPA144","genericName":"FPA144","slug":"fpa144","indication":"Gastric cancer and gastroesophageal junction cancer with FGFR2b overexpression","status":"phase_2"},{"name":"ABP 206","genericName":"ABP 206","slug":"abp-206","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"ABP 234","genericName":"ABP 234","slug":"abp-234","indication":"Giant cell tumor of bone","status":"phase_3"},{"name":"ABP 654","genericName":"ABP 654","slug":"abp-654","indication":"Giant cell tumor of bone","status":"phase_3"},{"name":"ABP 938","genericName":"ABP 938","slug":"abp-938","indication":"Osteoporosis in postmenopausal women","status":"phase_3"},{"name":"ABP 959","genericName":"ABP 959","slug":"abp-959","indication":"Giant cell tumor of bone","status":"phase_3"},{"name":"ABP 980","genericName":"ABP 980","slug":"abp-980","indication":"HER2-positive gastric cancer","status":"phase_3"},{"name":"AMG 162","genericName":"AMG 162","slug":"amg-162","indication":"Postmenopausal osteoporosis","status":"phase_3"},{"name":"AMG 162 / Denosumab","genericName":"AMG 162 / Denosumab","slug":"amg-162-denosumab","indication":"Postmenopausal osteoporosis","status":"phase_3"},{"name":"AMG 301","genericName":"AMG 301","slug":"amg-301","indication":"Multiple myeloma","status":"phase_2"},{"name":"AMG 386, paclitaxel and carboplatin","genericName":"AMG 386, paclitaxel and carboplatin","slug":"amg-386-paclitaxel-and-carboplatin","indication":"Ovarian cancer","status":"phase_1"},{"name":"AMG 410","genericName":"AMG 410","slug":"amg-410","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"AMG 719","genericName":"AMG 719","slug":"amg-719","indication":"Acute myeloid leukemia (AML), FLT3-positive","status":"phase_2"},{"name":"Adecatumumab and FOLFOX","genericName":"Adecatumumab and FOLFOX","slug":"adecatumumab-and-folfox","indication":"Colorectal cancer","status":"phase_2"},{"name":"Anti-angiogenesis","genericName":"Anti-angiogenesis","slug":"anti-angiogenesis","indication":"Treatment of various cancers","status":"phase_1"},{"name":"Bevacizumab-awwb","genericName":"Bevacizumab-awwb","slug":"bevacizumab-awwb","indication":"Metastatic colorectal cancer","status":"marketed"},{"name":"Darbepoetin alfa and Epoetin alfa","genericName":"Darbepoetin alfa and Epoetin alfa","slug":"darbepoetin-alfa-and-epoetin-alfa","indication":"Anemia associated with chronic kidney disease","status":"phase_3"},{"name":"Denosumab (AMG 162)","genericName":"Denosumab (AMG 162)","slug":"denosumab-amg-162","indication":"Prevention of skeletal-related events in patients with bone metastases from solid tumors","status":"phase_3"},{"name":"Denosumab (CP2)","genericName":"Denosumab (CP2)","slug":"denosumab-cp2","indication":"Prevention of skeletal-related events in patients with bone metastases from solid tumors","status":"phase_3"},{"name":"Denosumab (CP4)","genericName":"Denosumab (CP4)","slug":"denosumab-cp4","indication":"Prevention of skeletal-related events in patients with bone metastases from solid tumors","status":"phase_3"},{"name":"Drug: Carfilzomib + Dexamethasone","genericName":"Drug: Carfilzomib + Dexamethasone","slug":"drug-carfilzomib-dexamethasone","indication":"Multiple myeloma (relapsed or refractory)","status":"marketed"},{"name":"Drug: Carfilzomib + Lenalidomide + Dexamethasone","genericName":"Drug: Carfilzomib + Lenalidomide + Dexamethasone","slug":"drug-carfilzomib-lenalidomide-dexamethasone","indication":"Relapsed or refractory multiple myeloma","status":"marketed"},{"name":"EU-authorized Nivolumab","genericName":"EU-authorized Nivolumab","slug":"eu-authorized-nivolumab","indication":"Metastatic melanoma","status":"phase_3"},{"name":"FDA-licensed Nivolumab","genericName":"FDA-licensed Nivolumab","slug":"fda-licensed-nivolumab","indication":"Metastatic non-small cell lung cancer","status":"phase_3"},{"name":"HZT-501","genericName":"HZT-501","slug":"hzt-501","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"HyperCVAD","genericName":"HyperCVAD","slug":"hypercvad","indication":"Acute lymphoblastic leukemia (ALL)","status":"phase_3"},{"name":"Imlygic","genericName":"TALIMOGENE LAHERPAREPVEC","slug":"talimogene-laherparepvec","indication":"Local treatment of unresectable melanoma lesions","status":"marketed"},{"name":"Irinotecan Based Chemotherapy","genericName":"Irinotecan Based Chemotherapy","slug":"irinotecan-based-chemotherapy","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"KANJINTI","genericName":"TRASTUZUMAB-ANNS","slug":"trastuzumab-anns","indication":"Adjuvant Breast Cancer","status":"marketed"},{"name":"Low-intensity chemotherapy regimen","genericName":"Low-intensity chemotherapy regimen","slug":"low-intensity-chemotherapy-regimen","indication":"Hematologic malignancies in elderly or frail patients","status":"phase_3"},{"name":"Non-steroidal aromatase inhibitor therapy","genericName":"Non-steroidal aromatase inhibitor therapy","slug":"non-steroidal-aromatase-inhibitor-therapy","indication":"Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant or metastatic setting)","status":"phase_3"},{"name":"Ocrelizumab (EU)","genericName":"Ocrelizumab (EU)","slug":"ocrelizumab-eu","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"},{"name":"Oxaliplatin Based Chemotherapy","genericName":"Oxaliplatin Based Chemotherapy","slug":"oxaliplatin-based-chemotherapy","indication":"Metastatic colorectal cancer (in combination with fluorouracil and leucovorin)","status":"phase_3"},{"name":"Pembrolizumab (EU)","genericName":"Pembrolizumab (EU)","slug":"pembrolizumab-eu","indication":"Metastatic melanoma","status":"phase_3"},{"name":"Placebo to Denosumab","genericName":"Placebo to Denosumab","slug":"placebo-to-denosumab","indication":"Postmenopausal osteoporosis in women at high risk of fracture","status":"marketed"},{"name":"Placebo to Methotrexate","genericName":"Placebo to Methotrexate","slug":"placebo-to-methotrexate","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Placebo to zoledronic acid","genericName":"Placebo to zoledronic acid","slug":"placebo-to-zoledronic-acid","indication":"Hypercalcemia of malignancy","status":"marketed"},{"name":"Rituximab (EU)","genericName":"Rituximab (EU)","slug":"rituximab-eu","indication":"Non-Hodgkin's lymphoma","status":"phase_3"},{"name":"Rituximab (US)","genericName":"Rituximab (US)","slug":"rituximab-us","indication":"Non-Hodgkin's lymphoma (B-cell)","status":"phase_3"},{"name":"Sensipar","genericName":"CINACALCET","slug":"cinacalcet","indication":"Hypercalcemia due to Primary Hyperparathyroidism","status":"marketed"},{"name":"Trifluridine and Tipiracil","genericName":"Trifluridine and Tipiracil","slug":"trifluridine-and-tipiracil","indication":"Metastatic colorectal cancer (previously treated)","status":"marketed"},{"name":"rHuEPO","genericName":"rHuEPO","slug":"rhuepo","indication":"Anemia associated with chronic kidney disease","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":2400000000,"percentOfTotal":14.4,"drugCount":8,"colorKey":"infectious","drugs":[{"name":"Neulasta","genericName":"Pegfilgrastim-Apgf","slug":"nyvepria","indication":"Allogeneic peripheral blood stem cell transplant","status":"marketed","revenue":1200000000},{"name":"Epogen","genericName":"Epoetin Alfa-Epbx","slug":"retacrit","indication":"Anemia due to chemotherapy","status":"marketed","revenue":400000000},{"name":"Aranesp","genericName":"DARBEPOETIN ALFA","slug":"darbepoetin-alfa","indication":"Anemia due to and following chemotherapy","status":"marketed","revenue":400000000},{"name":"Epogen","genericName":"EPOETIN ALFA","slug":"epoetin-alfa","indication":"Anemia due to chemotherapy","status":"marketed","revenue":400000000},{"name":"Aranesp® (darbepoetin alfa)","genericName":"Aranesp® (darbepoetin alfa)","slug":"aranesp-darbepoetin-alfa","indication":"Anemia associated with chronic kidney disease","status":"phase_3"},{"name":"Neulasta","genericName":"PEGFILGRASTIM","slug":"pegfilgrastim","indication":"Allogeneic peripheral blood stem cell transplant","status":"marketed"},{"name":"Neulasta® (pegfilgrastim)","genericName":"Neulasta® (pegfilgrastim)","slug":"neulasta-pegfilgrastim","indication":"Chemotherapy-induced neutropenia (CIN) in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy","status":"marketed"},{"name":"darbepoetin alfa SF","genericName":"darbepoetin alfa SF","slug":"darbepoetin-alfa-sf","indication":"Treatment of anemia associated with chronic kidney disease","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":2100000000,"percentOfTotal":12.6,"drugCount":27,"colorKey":"immunology","drugs":[{"name":"Otezla","genericName":"APREMILAST","slug":"apremilast","indication":"Behçet's disease affecting oral mucosa","status":"marketed","revenue":2100000000},{"name":"1=Etanercept","genericName":"1=Etanercept","slug":"1-etanercept","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"ABP 501","genericName":"ABP 501","slug":"abp-501","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"ABP 710","genericName":"ABP 710","slug":"abp-710","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"AMG 531","genericName":"AMG 531","slug":"amg-531","indication":"Chronic immune thrombocytopenia (ITP)","status":"phase_3"},{"name":"AMG 714","genericName":"AMG 714","slug":"amg-714","indication":"Rheumatoid arthritis","status":"phase_2"},{"name":"Anakinra (r-metHuIL-1ra)","genericName":"Anakinra (r-metHuIL-1ra)","slug":"anakinra-r-methuil-1ra","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"Apremilast Modified Release 13","genericName":"Apremilast Modified Release 13","slug":"apremilast-modified-release-13","indication":"Plaque psoriasis","status":"phase_1"},{"name":"CCX-354-C","genericName":"CCX-354-C","slug":"ccx-354-c","indication":"Inflammatory and autoimmune conditions (specific indication under investigation)","status":"phase_2"},{"name":"Commercial Formulation Etanercept","genericName":"Commercial Formulation Etanercept","slug":"commercial-formulation-etanercept","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Enbrel liquid","genericName":"Enbrel liquid","slug":"enbrel-liquid","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Etanercept (ENBREL®)","genericName":"Etanercept (ENBREL®)","slug":"etanercept-enbrel","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"Etanercept / Autoinjector A","genericName":"Etanercept / Autoinjector A","slug":"etanercept-autoinjector-a","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Etanercept Liquid","genericName":"Etanercept Liquid","slug":"etanercept-liquid","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Etanercept via Autoinjector A","genericName":"Etanercept via Autoinjector A","slug":"etanercept-via-autoinjector-a","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"Etanercept via Autoinjector B","genericName":"Etanercept via Autoinjector B","slug":"etanercept-via-autoinjector-b","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"Kineret® (Anakinra)","genericName":"Kineret® (Anakinra)","slug":"kineret-anakinra","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"MR prednisone","genericName":"MR prednisone","slug":"mr-prednisone","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Medical Standard of Care for ITP","genericName":"Medical Standard of Care for ITP","slug":"medical-standard-of-care-for-itp","indication":"Immune thrombocytopenia (ITP)","status":"phase_3"},{"name":"New Formulation Etanercept","genericName":"New Formulation Etanercept","slug":"new-formulation-etanercept","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Placebo for etanercept subcutaneous injection","genericName":"Placebo for etanercept subcutaneous injection","slug":"placebo-for-etanercept-subcutaneous-injection","indication":"Treatment of moderate to severe rheumatoid arthritis","status":"phase_3"},{"name":"Placebo-Apremilast","genericName":"Placebo-Apremilast","slug":"placebo-apremilast","indication":"Plaque psoriasis","status":"marketed"},{"name":"Topical treatments or phototherapy","genericName":"Topical treatments or phototherapy","slug":"topical-treatments-or-phototherapy","indication":"Psoriasis","status":"phase_3"},{"name":"VIMOVO 250/20","genericName":"VIMOVO 250/20","slug":"vimovo-250-20","indication":"Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk for NSAID-induced gastric ulcers","status":"marketed"},{"name":"VIMOVO 375/20","genericName":"VIMOVO 375/20","slug":"vimovo-375-20","indication":"Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk for NSAID-induced gastric ulcers","status":"marketed"},{"name":"VIMOVO 500/20","genericName":"VIMOVO 500/20","slug":"vimovo-500-20","indication":"Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk for NSAID-induced gastric ulcers","status":"marketed"},{"name":"WEZLANA","genericName":"USTEKINUMAB-AUUB","slug":"ustekinumab-auub","indication":"Moderate to Severe Plaque Psoriasis","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":1524000000,"percentOfTotal":9.1,"drugCount":8,"colorKey":"cardiovascular","drugs":[{"name":"Nplate","genericName":"ROMIPLOSTIM","slug":"romiplostim","indication":"Aplastic anemia","status":"marketed","revenue":1524000000},{"name":"AMG 853","genericName":"AMG 853","slug":"amg-853","indication":"Reduction of the risk of thrombotic events in patients with acute coronary syndrome or myocardial infarction","status":"phase_2"},{"name":"Background Statin Therapy","genericName":"Background Statin Therapy","slug":"background-statin-therapy","indication":"Hypercholesterolemia and cardiovascular risk reduction (used as background therapy in clinical trials)","status":"phase_3"},{"name":"Corlanor","genericName":"IVABRADINE","slug":"ivabradine","indication":"Angina pectoris","status":"marketed"},{"name":"Evolocumab AI/pen","genericName":"Evolocumab AI/pen","slug":"evolocumab-ai-pen","indication":"Hypercholesterolemia (primary and secondary prevention of cardiovascular disease)","status":"phase_3"},{"name":"Evolocumab Pre-filled Syringe","genericName":"Evolocumab Pre-filled Syringe","slug":"evolocumab-pre-filled-syringe","indication":"Hypercholesterolemia (primary and secondary prevention of cardiovascular events)","status":"phase_3"},{"name":"Placebo to Atorvastatin","genericName":"Placebo to Atorvastatin","slug":"placebo-to-atorvastatin","indication":"Hypercholesterolemia and cardiovascular risk reduction (specific indication dependent on Phase 3 trial design)","status":"phase_3"},{"name":"Placebo to Ezetimibe","genericName":"Placebo to Ezetimibe","slug":"placebo-to-ezetimibe","indication":"Hypercholesterolemia (primary and secondary prevention of cardiovascular disease)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":500000000,"percentOfTotal":3,"drugCount":5,"colorKey":"respiratory","drugs":[{"name":"Aimovig","genericName":"ERENUMAB","slug":"erenumab","indication":"Migraine","status":"marketed","revenue":500000000},{"name":"ABP 692","genericName":"ABP 692","slug":"abp-692","indication":"Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)","status":"phase_3"},{"name":"AMG 334 Dose 1","genericName":"AMG 334 Dose 1","slug":"amg-334-dose-1","indication":"Migraine prevention","status":"phase_2"},{"name":"Erenumab Dose 1","genericName":"Erenumab Dose 1","slug":"erenumab-dose-1","indication":"Episodic migraine prevention","status":"phase_3"},{"name":"erenumab-aooe","genericName":"erenumab-aooe","slug":"erenumab-aooe","indication":"Migraine prevention in adults","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"rare","drugs":[{"name":"Buphenyl","genericName":"Buphenyl","slug":"buphenyl","indication":"Amyotrophic lateral sclerosis","status":"marketed"},{"name":"ABX-EGF","genericName":"ABX-EGF","slug":"abx-egf","indication":"Diabetic foot ulcers","status":"phase_2"},{"name":"AMG 193","genericName":"AMG 193","slug":"amg-193","indication":"Hypercholesterolemia","status":"phase_2"},{"name":"AMG 223","genericName":"AMG 223","slug":"amg-223","indication":"Hypercholesterolemia","status":"phase_2"},{"name":"Placebo to Evolocumab","genericName":"Placebo to Evolocumab","slug":"placebo-to-evolocumab","indication":"Hypercholesterolemia","status":"phase_3"},{"name":"RP103","genericName":"RP103","slug":"rp103","indication":"Hypercholesterolemia","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"ophthalmology","drugs":[{"name":"Evolocumab AMD","genericName":"Evolocumab AMD","slug":"evolocumab-amd","indication":"Age-related macular degeneration (AMD) — investigational indication in Phase 3","status":"phase_3"},{"name":"TEPEZZA","genericName":"TEPEZZA","slug":"tepezza","indication":"Moderate-to-severe thyroid eye disease (TED)","status":"marketed"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"Topical agents","genericName":"Topical agents","slug":"topical-agents","indication":"Eczema","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"dermatology","drugs":[{"name":"Ibuprofen/famotidine","genericName":"Ibuprofen/famotidine","slug":"ibuprofen-famotidine","indication":"Chronic pain conditions where NSAID use is indicated, with reduced gastrointestinal risk","status":"phase_3"}]}],"pipeline":[{"name":"Prolia","genericName":"DENOSUMAB","slug":"denosumab","phase":"marketed","mechanism":"Prolia works by blocking a protein that breaks down bone.","indications":["Drug-induced osteoporosis","Osteoporosis","Postmenopausal osteoporosis"],"catalyst":""},{"name":"Otezla","genericName":"APREMILAST","slug":"apremilast","phase":"marketed","mechanism":"Apremilast inhibits PDE4, increasing intracellular cAMP levels, but the exact therapeutic mechanism is unclear.","indications":["Behçet's disease affecting oral mucosa","Plaque psoriasis","Psoriasis with arthropathy"],"catalyst":""},{"name":"Nplate","genericName":"ROMIPLOSTIM","slug":"romiplostim","phase":"marketed","mechanism":"Nplate works by binding to the thrombopoietin receptor to stimulate platelet production.","indications":["Aplastic anemia","Chronic idiopathic thrombocytopenic purpura"],"catalyst":""},{"name":"Neupogen","genericName":"Filgrastim-Aafi","slug":"nivestym","phase":"marketed","mechanism":"Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation.","indications":["Chemotherapy-induced neutropenia","Chronic idiopathic neutropenia","Congenital neutropenia","Cyclical neutropenia","Enhancement of an antitumor effect of dinutuximab for neuroblastoma"],"catalyst":""},{"name":"Kyprolis","genericName":"carfilzomib","slug":"carfilzomib","phase":"marketed","mechanism":"Kyprolis works by blocking the proteasome, a complex that breaks down proteins in cells.","indications":["Multiple myeloma","Relapse multiple myeloma"],"catalyst":""},{"name":"Neulasta","genericName":"Pegfilgrastim-Apgf","slug":"nyvepria","phase":"marketed","mechanism":"Colony-stimulating factor binding hematopoietic cell surface receptors to stimulate proliferation and differentiation.","indications":["Allogeneic peripheral blood stem cell transplant","Chemotherapy-induced neutropenia"],"catalyst":""},{"name":"Blincyto","genericName":"blinatumomab","slug":"blinatumomab","phase":"marketed","mechanism":"Blincyto works by binding to both T cells and cancer cells, directing the T cells to kill the cancer cells.","indications":["Pre B-cell acute lymphoblastic leukemia"],"catalyst":""},{"name":"Aimovig","genericName":"ERENUMAB","slug":"erenumab","phase":"marketed","mechanism":"Aimovig works by blocking the calcitonin-gene-related peptide receptor, a protein involved in migraine pain.","indications":["Migraine","Prevention of migraine attacks"],"catalyst":""},{"name":"Epogen","genericName":"Epoetin Alfa-Epbx","slug":"retacrit","phase":"marketed","mechanism":"Epoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.","indications":["Anemia due to chemotherapy","Anemia in chronic kidney disease"],"catalyst":""},{"name":"Aranesp","genericName":"DARBEPOETIN ALFA","slug":"darbepoetin-alfa","phase":"marketed","mechanism":"Aranesp works by binding to the erythropoietin receptor, mimicking the action of natural erythropoietin to stimulate red blood cell production.","indications":["Anemia due to and following chemotherapy","Anemia of renal disease"],"catalyst":""},{"name":"Epogen","genericName":"EPOETIN ALFA","slug":"epoetin-alfa","phase":"marketed","mechanism":"Epogen works by binding to the erythropoietin receptor, triggering a cascade of signals that stimulate the production of red blood cells.","indications":["Anemia due to chemotherapy","Anemia in chronic kidney disease"],"catalyst":""},{"name":"Lumakras","genericName":"SOTORASIB","slug":"sotorasib","phase":"marketed","mechanism":"Lumakras works by covalently binding to the KRAS G12C mutation, thereby blocking the protein's ability to promote cancer cell growth.","indications":["KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer"],"catalyst":""},{"name":"AB248","genericName":"AB248","slug":"ab248","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABP 798","genericName":"ABP 798","slug":"abp-798","phase":"phase_3","mechanism":"ABP 798 is a bispecific antibody that simultaneously engages CD3 on T cells and PMEL (gp100) on melanoma cells to redirect immune attack against melanoma tumors.","indications":["Metastatic melanoma (PMEL-positive)"],"catalyst":""},{"name":"AMG334","genericName":"AMG334","slug":"amg334","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Buphenyl","genericName":"Buphenyl","slug":"buphenyl","phase":"marketed","mechanism":"Aldose reductase, Histone deacetylase 1, Histone deacetylase 2","indications":["Amyotrophic lateral sclerosis","Citrullinemia","Congenital hyperammonemia, type I","Deficiency of carbamylphosphate synthetase (CPS)","Disorder of the urea cycle metabolism"],"catalyst":""},{"name":"CCX354-C","genericName":"CCX354-C","slug":"ccx354-c","phase":"phase_2","mechanism":"CCX354-C is a monoclonal antibody that targets the IL-1 receptor antagonist (IL-1RA) to prevent IL-1 mediated inflammation.","indications":["Treatment of Still's disease"],"catalyst":""},{"name":"Etanerept","genericName":"Etanerept","slug":"etanerept","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Evenity","genericName":"romosozumab","slug":"romosozumab","phase":"marketed","mechanism":"Sclerostin","indications":["Postmenopausal osteoporosis"],"catalyst":""},{"name":"FPA144","genericName":"FPA144","slug":"fpa144","phase":"phase_2","mechanism":"FPA144 is a monoclonal antibody that blocks fibroblast growth factor receptor 2b (FGFR2b) to inhibit tumor growth and angiogenesis.","indications":["Gastric cancer and gastroesophageal junction cancer with FGFR2b overexpression"],"catalyst":""},{"name":"Topical agents","genericName":"Topical agents","slug":"topical-agents","phase":"phase_3","mechanism":"Topical agents work by directly applying a medication to the skin to treat various conditions.","indications":["Eczema","Acne","Wound healing"],"catalyst":""},{"name":"1=Etanercept","genericName":"1=Etanercept","slug":"1-etanercept","phase":"phase_3","mechanism":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Juvenile idiopathic arthritis","Plaque psoriasis"],"catalyst":""},{"name":"ABP 206","genericName":"ABP 206","slug":"abp-206","phase":"phase_3","mechanism":"ABP 206 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.","indications":["Metastatic colorectal cancer","Non-squamous non-small cell lung cancer","Metastatic breast cancer","Renal cell carcinoma"],"catalyst":""},{"name":"ABP 234","genericName":"ABP 234","slug":"abp-234","phase":"phase_3","mechanism":"ABP 234 is a RANKL inhibitor that blocks osteoclast activation and bone resorption.","indications":["Giant cell tumor of bone","Bone metastases"],"catalyst":""},{"name":"ABP 501","genericName":"ABP 501","slug":"abp-501","phase":"phase_3","mechanism":"ABP 501 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"ABP 501-HCF","genericName":"ABP 501-HCF","slug":"abp-501-hcf","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABP 501-LCF","genericName":"ABP 501-LCF","slug":"abp-501-lcf","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABP 654","genericName":"ABP 654","slug":"abp-654","phase":"phase_3","mechanism":"ABP 654 is a monoclonal antibody that blocks RANKL (receptor activator of nuclear factor kappa-B ligand) to inhibit osteoclast formation and bone resorption.","indications":["Giant cell tumor of bone","Bone metastases in solid tumors"],"catalyst":""},{"name":"ABP 692","genericName":"ABP 692","slug":"abp-692","phase":"phase_3","mechanism":"ABP 692 is a monoclonal antibody that targets amyloid-beta protofibrils to reduce amyloid pathology in Alzheimer's disease.","indications":["Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)"],"catalyst":""},{"name":"ABP 710","genericName":"ABP 710","slug":"abp-710","phase":"phase_3","mechanism":"ABP 710 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Psoriasis","Psoriatic arthritis"],"catalyst":""},{"name":"ABP 938","genericName":"ABP 938","slug":"abp-938","phase":"phase_3","mechanism":"ABP 938 is a RANKL inhibitor that blocks osteoclast activation and bone resorption.","indications":["Osteoporosis in postmenopausal women","Bone loss in patients with hormone-sensitive prostate cancer receiving androgen deprivation therapy"],"catalyst":""},{"name":"ABP 959","genericName":"ABP 959","slug":"abp-959","phase":"phase_3","mechanism":"ABP 959 is a RANKL inhibitor that blocks osteoclast activation and bone resorption.","indications":["Giant cell tumor of bone","Bone metastases"],"catalyst":""},{"name":"ABP 980","genericName":"ABP 980","slug":"abp-980","phase":"phase_3","mechanism":"ABP 980 is a HER2-targeting antibody-drug conjugate that delivers cytotoxic payload to HER2-expressing cancer cells.","indications":["HER2-positive gastric cancer","HER2-positive breast cancer"],"catalyst":""},{"name":"ABX-EGF","genericName":"ABX-EGF","slug":"abx-egf","phase":"phase_2","mechanism":"ABX-EGF is a recombinant human heparin-binding EGF-like growth factor.","indications":["Diabetic foot ulcers"],"catalyst":""},{"name":"AGM 719","genericName":"AGM 719","slug":"agm-719","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 073","genericName":"AMG 073","slug":"amg-073","phase":"marketed","mechanism":"AMG 073 is a calcimimetic agent that allosterically activates the calcium-sensing receptor on the parathyroid gland, increasing its sensitivity to extracellular calcium and thereby suppressing parathyroid hormone secretion.","indications":["Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis"],"catalyst":""},{"name":"AMG 133","genericName":"AMG 133","slug":"amg-133","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 162","genericName":"AMG 162","slug":"amg-162","phase":"phase_3","mechanism":"AMG 162 is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation and bone resorption.","indications":["Postmenopausal osteoporosis","Prevention of skeletal-related events in patients with bone metastases from solid tumors"],"catalyst":""},{"name":"AMG 162 - Prolia","genericName":"AMG 162 - Prolia","slug":"amg-162-prolia","phase":"phase_2","mechanism":"AMG 162, also known as Prolia, is a human monoclonal antibody that targets RANKL, a protein involved in bone resorption.","indications":["Treatment of osteoporosis in postmenopausal women","Treatment of bone loss in patients with glucocorticoid-induced osteoporosis"],"catalyst":""},{"name":"AMG 162 / Denosumab","genericName":"AMG 162 / Denosumab","slug":"amg-162-denosumab","phase":"phase_3","mechanism":"Denosumab is a monoclonal antibody that inhibits RANKL, a key regulator of osteoclast formation and bone resorption.","indications":["Postmenopausal osteoporosis","Bone loss in patients with cancer receiving aromatase inhibitors or androgen deprivation therapy","Prevention of skeletal-related events in patients with bone metastases from solid tumors","Giant cell tumor of bone"],"catalyst":""},{"name":"AMG 172","genericName":"AMG 172","slug":"amg-172","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 193","genericName":"AMG 193","slug":"amg-193","phase":"phase_2","mechanism":"AMG 193 is a monoclonal antibody targeting PCSK9.","indications":["Hypercholesterolemia"],"catalyst":""},{"name":"AMG 223","genericName":"AMG 223","slug":"amg-223","phase":"phase_2","mechanism":"AMG 223 is a human monoclonal antibody that targets PCSK9.","indications":["Hypercholesterolemia"],"catalyst":""},{"name":"AMG 256","genericName":"AMG 256","slug":"amg-256","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 282","genericName":"AMG 282","slug":"amg-282","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 301","genericName":"AMG 301","slug":"amg-301","phase":"phase_2","mechanism":"AMG 301 is a monoclonal antibody targeting the interleukin-1 receptor type 1 (IL1R1).","indications":["Multiple myeloma"],"catalyst":""},{"name":"AMG 305","genericName":"AMG 305","slug":"amg-305","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 334 Dose 1","genericName":"AMG 334 Dose 1","slug":"amg-334-dose-1","phase":"phase_2","mechanism":"AMG 334 is a fully human monoclonal antibody that targets and inhibits the activity of the calcitonin gene-related peptide (CGRP) receptor.","indications":["Migraine prevention"],"catalyst":""},{"name":"AMG 355","genericName":"AMG 355","slug":"amg-355","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 386, paclitaxel and carboplatin","genericName":"AMG 386, paclitaxel and carboplatin","slug":"amg-386-paclitaxel-and-carboplatin","phase":"phase_1","mechanism":"Angiopoietin-2 inhibitor","indications":["Ovarian cancer","Breast cancer"],"catalyst":""},{"name":"AMG 403","genericName":"AMG 403","slug":"amg-403","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 410","genericName":"AMG 410","slug":"amg-410","phase":"phase_1","mechanism":"Antibody-drug conjugate targeting fibroblast growth factor receptor 3 (FGFR3)","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"AMG 436","genericName":"AMG 436","slug":"amg-436","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 509","genericName":"AMG 509","slug":"amg-509","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 513","genericName":"AMG 513","slug":"amg-513","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 529","genericName":"AMG 529","slug":"amg-529","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 531","genericName":"AMG 531","slug":"amg-531","phase":"phase_3","mechanism":"AMG 531 is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on megakaryocytes.","indications":["Chronic immune thrombocytopenia (ITP)","Thrombocytopenia in patients with chronic hepatitis C"],"catalyst":""},{"name":"AMG 570","genericName":"AMG 570","slug":"amg-570","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AMG 581","genericName":"AMG 581","slug":"amg-581","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 592","genericName":"AMG 592","slug":"amg-592","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 595","genericName":"AMG 595","slug":"amg-595","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 598","genericName":"AMG 598","slug":"amg-598","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 609","genericName":"AMG 609","slug":"amg-609","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 623","genericName":"AMG 623","slug":"amg-623","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 691","genericName":"AMG 691","slug":"amg-691","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 714","genericName":"AMG 714","slug":"amg-714","phase":"phase_2","mechanism":"AMG 714 is an interleukin-6 (IL-6) receptor antagonist that blocks IL-6 signaling to reduce inflammation.","indications":["Rheumatoid arthritis","Systemic lupus erythematosus"],"catalyst":""},{"name":"AMG 719","genericName":"AMG 719","slug":"amg-719","phase":"phase_2","mechanism":"AMG 719 is a bispecific antibody that simultaneously engages CD3 on T cells and FLT3 on acute myeloid leukemia blasts to redirect immune killing.","indications":["Acute myeloid leukemia (AML), FLT3-positive"],"catalyst":""},{"name":"AMG 732","genericName":"AMG 732","slug":"amg-732","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 786","genericName":"AMG 786","slug":"amg-786","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 853","genericName":"AMG 853","slug":"amg-853","phase":"phase_2","mechanism":"AMG 853 is a recombinant, humanized monoclonal antibody that targets and neutralizes tissue factor.","indications":["Reduction of the risk of thrombotic events in patients with acute coronary syndrome or myocardial infarction"],"catalyst":""},{"name":"AMG 890","genericName":"AMG 890","slug":"amg-890","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 986","genericName":"AMG 986","slug":"amg-986","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG 994","genericName":"AMG 994","slug":"amg-994","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AVSOLA","genericName":"INFLIXIMAB-AXXQ","slug":"infliximab-axxq","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Actonel®","genericName":"Actonel®","slug":"actonel","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Adecatumumab and FOLFOX","genericName":"Adecatumumab and FOLFOX","slug":"adecatumumab-and-folfox","phase":"phase_2","mechanism":"Adecatumumab is a monoclonal antibody targeting EpCAM, while FOLFOX is a chemotherapy regimen combining oxaliplatin, 5-fluorouracil, and leucovorin.","indications":["Colorectal cancer"],"catalyst":""},{"name":"Aeroquin","genericName":"Aeroquin","slug":"aeroquin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ammonul","genericName":"Ammonul","slug":"ammonul","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Anakinra (r-metHuIL-1ra)","genericName":"Anakinra (r-metHuIL-1ra)","slug":"anakinra-r-methuil-1ra","phase":"marketed","mechanism":"Anakinra is a recombinant interleukin-1 receptor antagonist that blocks IL-1 signaling to reduce inflammation.","indications":["Rheumatoid arthritis","Autoinflammatory syndromes (e.g., cryopyrin-associated periodic syndromes)","Gout"],"catalyst":""},{"name":"Anti-angiogenesis","genericName":"Anti-angiogenesis","slug":"anti-angiogenesis","phase":"phase_1","mechanism":"Inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF)","indications":["Treatment of various cancers"],"catalyst":""},{"name":"Antizol","genericName":"Antizol","slug":"antizol","phase":"marketed","mechanism":"Alcohol dehydrogenase, Alcohol dehydrogenase","indications":["Accidental poisoning by methyl alcohol","Ethylene Glycol Toxicity"],"catalyst":""},{"name":"Apremilast 30mg","genericName":"Apremilast 30mg","slug":"apremilast-30mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Apremilast IR","genericName":"Apremilast IR","slug":"apremilast-ir","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Apremilast Modified Release 13","genericName":"Apremilast Modified Release 13","slug":"apremilast-modified-release-13","phase":"phase_1","mechanism":"Apremilast is a small molecule inhibitor of phosphodiesterase 4 (PDE4), which leads to increased intracellular levels of cyclic adenosine monophosphate (cAMP).","indications":["Plaque psoriasis","Psoriatic arthritis"],"catalyst":""},{"name":"Apremilast Modified Release 14","genericName":"Apremilast Modified Release 14","slug":"apremilast-modified-release-14","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Apremilast Modified Release 4","genericName":"Apremilast Modified Release 4","slug":"apremilast-modified-release-4","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Apremilast Modified Release 8","genericName":"Apremilast Modified Release 8","slug":"apremilast-modified-release-8","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Apremilast Modified Release 9","genericName":"Apremilast Modified Release 9","slug":"apremilast-modified-release-9","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Aranesp® (darbepoetin alfa)","genericName":"Aranesp® (darbepoetin alfa)","slug":"aranesp-darbepoetin-alfa","phase":"phase_3","mechanism":"Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production.","indications":["Anemia associated with chronic kidney disease","Anemia in patients with non-myeloid malignancies receiving chemotherapy","Anemia of chronic disease"],"catalyst":""},{"name":"Arm 1- Dose Expansion","genericName":"Arm 1- Dose Expansion","slug":"arm-1-dose-expansion","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BKEMV","genericName":"ECULIZUMAB-AEEB","slug":"eculizumab-aeeb","phase":"marketed","mechanism":"","indications":["Paroxysmal Nocturnal Hemoglobinuria (PNH)","Atypical Hemolytic Uremic Syndrome (aHUS)","Generalized Myasthenia Gravis (gMG)"],"catalyst":""},{"name":"Background Statin Therapy","genericName":"Background Statin Therapy","slug":"background-statin-therapy","phase":"phase_3","mechanism":"Background statin therapy reduces low-density lipoprotein (LDL) cholesterol by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis.","indications":["Hypercholesterolemia and cardiovascular risk reduction (used as background therapy in clinical trials)"],"catalyst":""},{"name":"Bevacizumab-awwb","genericName":"Bevacizumab-awwb","slug":"bevacizumab-awwb","phase":"marketed","mechanism":"Bevacizumab-awwb is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells.","indications":["Metastatic colorectal cancer","Non-squamous non-small cell lung cancer","Metastatic breast cancer","Recurrent glioblastoma","Metastatic renal cell carcinoma"],"catalyst":""},{"name":"Buphenyl (NaPBA)","genericName":"Buphenyl (NaPBA)","slug":"buphenyl-napba","phase":"phase_3","mechanism":"Buphenyl (sodium phenylbutyrate) provides an alternative pathway for nitrogen excretion by conjugating with glutamine to form phenylacetylglutamine, which is then renally eliminated.","indications":["Urea cycle disorders (hyperammonemia management)"],"catalyst":""},{"name":"CC-10004","genericName":"CC-10004","slug":"cc-10004","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CC10004","genericName":"CC10004","slug":"cc10004","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CCX-354-C","genericName":"CCX-354-C","slug":"ccx-354-c","phase":"phase_2","mechanism":"CCX-354-C is a C-C chemokine receptor 4 (CCR4) antagonist that blocks immune cell recruitment to reduce inflammatory responses.","indications":["Inflammatory and autoimmune conditions (specific indication under investigation)"],"catalyst":""},{"name":"CCX282-B","genericName":"CCX282-B","slug":"ccx282-b","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Carboplatin, pemetrexed, docetaxel, paclitaxel","genericName":"Carboplatin, pemetrexed, docetaxel, paclitaxel","slug":"carboplatin-pemetrexed-docetaxel-paclitaxel","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Commercial Formulation Etanercept","genericName":"Commercial Formulation Etanercept","slug":"commercial-formulation-etanercept","phase":"phase_3","mechanism":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.","indications":["Rheumatoid arthritis","Ankylosing spondylitis","Psoriatic arthritis","Juvenile idiopathic arthritis","Plaque psoriasis"],"catalyst":""},{"name":"Corlanor","genericName":"IVABRADINE","slug":"ivabradine","phase":"marketed","mechanism":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1","indications":["Angina pectoris","Chronic heart failure"],"catalyst":""},{"name":"Cysteamine Bitartrate Delayed-release Capsules","genericName":"Cysteamine Bitartrate Delayed-release Capsules","slug":"cysteamine-bitartrate-delayed-release-capsules","phase":"phase_3","mechanism":"Cysteamine bitartrate reduces cystine accumulation in lysosomes by converting cystine to cysteine and cysteamine, thereby decreasing intracellular cystine levels.","indications":["Cystinosis (nephropathic cystinosis)"],"catalyst":""},{"name":"DMARD Therapy","genericName":"DMARD Therapy","slug":"dmard-therapy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Darbepoetin alfa and Epoetin alfa","genericName":"Darbepoetin alfa and Epoetin alfa","slug":"darbepoetin-alfa-and-epoetin-alfa","phase":"phase_3","mechanism":"Darbepoetin alfa and Epoetin alfa are erythropoiesis-stimulating agents that bind to the erythropoietin receptor on bone marrow progenitor cells to stimulate red blood cell production.","indications":["Anemia associated with chronic kidney disease","Anemia in patients with cancer receiving chemotherapy","Anemia in patients with HIV infection on antiretroviral therapy"],"catalyst":""},{"name":"Denosumab (AMG 162)","genericName":"Denosumab (AMG 162)","slug":"denosumab-amg-162","phase":"phase_3","mechanism":"Denosumab is a monoclonal antibody that inhibits RANKL, a key signaling molecule that activates osteoclasts and promotes bone resorption.","indications":["Prevention of skeletal-related events in patients with bone metastases from solid tumors","Treatment of osteoporosis in postmenopausal women and men at high risk of fracture","Giant cell tumor of bone"],"catalyst":""},{"name":"Denosumab (CP2)","genericName":"Denosumab (CP2)","slug":"denosumab-cp2","phase":"phase_3","mechanism":"Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation and bone resorption.","indications":["Prevention of skeletal-related events in patients with bone metastases from solid tumors","Treatment of giant cell tumor of bone","Osteoporosis in postmenopausal women and men at high risk of fracture"],"catalyst":""},{"name":"Denosumab (CP4)","genericName":"Denosumab (CP4)","slug":"denosumab-cp4","phase":"phase_3","mechanism":"Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation and bone resorption.","indications":["Prevention of skeletal-related events in patients with bone metastases from solid tumors","Treatment of giant cell tumor of bone","Osteoporosis in postmenopausal women and men at high risk of fracture"],"catalyst":""},{"name":"Drug: Carfilzomib + Dexamethasone","genericName":"Drug: Carfilzomib + Dexamethasone","slug":"drug-carfilzomib-dexamethasone","phase":"marketed","mechanism":"Carfilzomib inhibits the proteasome to trigger cancer cell death, while dexamethasone is a corticosteroid that enhances anti-myeloma effects and reduces inflammation.","indications":["Multiple myeloma (relapsed or refractory)","Multiple myeloma (newly diagnosed)"],"catalyst":""},{"name":"Drug: Carfilzomib + Lenalidomide + Dexamethasone","genericName":"Drug: Carfilzomib + Lenalidomide + Dexamethasone","slug":"drug-carfilzomib-lenalidomide-dexamethasone","phase":"marketed","mechanism":"This three-drug combination kills multiple myeloma cells by inhibiting the proteasome, enhancing immune response to tumor cells, and suppressing tumor-promoting inflammation.","indications":["Relapsed or refractory multiple myeloma","Newly diagnosed multiple myeloma"],"catalyst":""},{"name":"EU-authorized Nivolumab","genericName":"EU-authorized Nivolumab","slug":"eu-authorized-nivolumab","phase":"phase_3","mechanism":"Nivolumab is a monoclonal antibody that blocks PD-1 on T cells, preventing tumor cells from evading immune attack.","indications":["Metastatic melanoma","Non-small cell lung cancer (NSCLC)","Renal cell carcinoma (RCC)","Classical Hodgkin lymphoma","Squamous cell carcinoma of the head and neck"],"catalyst":""},{"name":"EVENITY","genericName":"ROMOSOZUMAB-AQQG","slug":"romosozumab-aqqg","phase":"marketed","mechanism":"Sclerostin","indications":["Postmenopausal osteoporosis"],"catalyst":""},{"name":"Enbrel liquid","genericName":"Enbrel liquid","slug":"enbrel-liquid","phase":"phase_3","mechanism":"Enbrel is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine driving autoimmune and inflammatory diseases.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Polyarticular juvenile idiopathic arthritis","Plaque psoriasis"],"catalyst":""},{"name":"Erenumab 140 mg","genericName":"Erenumab 140 mg","slug":"erenumab-140-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Erenumab 70 mg","genericName":"Erenumab 70 mg","slug":"erenumab-70-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Erenumab Dose 1","genericName":"Erenumab Dose 1","slug":"erenumab-dose-1","phase":"phase_3","mechanism":"Erenumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.","indications":["Episodic migraine prevention","Chronic migraine prevention"],"catalyst":""},{"name":"Etanercept (ENBREL®)","genericName":"Etanercept (ENBREL®)","slug":"etanercept-enbrel","phase":"marketed","mechanism":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine driving immune-mediated diseases.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Polyarticular juvenile idiopathic arthritis","Plaque psoriasis"],"catalyst":""},{"name":"Etanercept / Autoinjector A","genericName":"Etanercept / Autoinjector A","slug":"etanercept-autoinjector-a","phase":"phase_3","mechanism":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.","indications":["Rheumatoid arthritis","Ankylosing spondylitis","Psoriatic arthritis","Juvenile idiopathic arthritis","Plaque psoriasis"],"catalyst":""},{"name":"Etanercept Liquid","genericName":"Etanercept Liquid","slug":"etanercept-liquid","phase":"phase_3","mechanism":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Polyarticular juvenile idiopathic arthritis","Plaque psoriasis"],"catalyst":""},{"name":"Etanercept via Autoinjector A","genericName":"Etanercept via Autoinjector A","slug":"etanercept-via-autoinjector-a","phase":"marketed","mechanism":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.","indications":["Rheumatoid arthritis","Polyarticular juvenile idiopathic arthritis","Psoriatic arthritis","Ankylosing spondylitis","Plaque psoriasis"],"catalyst":""},{"name":"Etanercept via Autoinjector B","genericName":"Etanercept via Autoinjector B","slug":"etanercept-via-autoinjector-b","phase":"marketed","mechanism":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.","indications":["Rheumatoid arthritis","Polyarticular juvenile idiopathic arthritis","Ankylosing spondylitis","Psoriatic arthritis","Plaque psoriasis"],"catalyst":""},{"name":"Evolocumab AI/pen","genericName":"Evolocumab AI/pen","slug":"evolocumab-ai-pen","phase":"phase_3","mechanism":"Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream.","indications":["Hypercholesterolemia (primary and secondary prevention of cardiovascular disease)","Familial hypercholesterolemia"],"catalyst":""},{"name":"Evolocumab AMD","genericName":"Evolocumab AMD","slug":"evolocumab-amd","phase":"phase_3","mechanism":"Evolocumab is a PCSK9 inhibitor monoclonal antibody that binds to and inactivates PCSK9 protein, allowing LDL receptors to remain on cell surfaces and increase clearance of LDL cholesterol from the blood.","indications":["Age-related macular degeneration (AMD) — investigational indication in Phase 3"],"catalyst":""},{"name":"Evolocumab Pre-filled Syringe","genericName":"Evolocumab Pre-filled Syringe","slug":"evolocumab-pre-filled-syringe","phase":"phase_3","mechanism":"Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream.","indications":["Hypercholesterolemia (primary and secondary prevention of cardiovascular events)","Familial hypercholesterolemia"],"catalyst":""},{"name":"FDA-licensed Nivolumab","genericName":"FDA-licensed Nivolumab","slug":"fda-licensed-nivolumab","phase":"phase_3","mechanism":"Nivolumab blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.","indications":["Metastatic non-small cell lung cancer","Metastatic melanoma","Advanced renal cell carcinoma","Classical Hodgkin lymphoma","Squamous cell carcinoma of the head and neck"],"catalyst":""},{"name":"HPN-100","genericName":"HPN-100","slug":"hpn-100","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HZT-501","genericName":"HZT-501","slug":"hzt-501","phase":"phase_3","mechanism":"HZT-501 is a bispecific antibody that simultaneously engages two distinct immune pathways to enhance anti-tumor T-cell responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"HyperCVAD","genericName":"HyperCVAD","slug":"hypercvad","phase":"phase_3","mechanism":"HyperCVAD is a chemotherapy regimen that combines multiple cytotoxic agents to kill rapidly dividing cancer cells through DNA damage and cell cycle disruption.","indications":["Acute lymphoblastic leukemia (ALL)","Lymphoma","Chronic myeloid leukemia (CML) in blast phase"],"catalyst":""},{"name":"IMDELLTRA","genericName":"TARLATAMAB-DLLE","slug":"tarlatamab-dlle","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Ibuprofen/famotidine","genericName":"Ibuprofen/famotidine","slug":"ibuprofen-famotidine","phase":"phase_3","mechanism":"This combination drug reduces stomach acid (via famotidine, an H2-receptor antagonist) while providing anti-inflammatory and analgesic effects (via ibuprofen, an NSAID), designed to minimize gastrointestinal injury from NSAID use.","indications":["Chronic pain conditions where NSAID use is indicated, with reduced gastrointestinal risk"],"catalyst":""},{"name":"Imdelltra (Amg757)","genericName":"TARLATAMAB","slug":"tarlatamab","phase":"marketed","mechanism":"Imdeldtra works by binding to a specific target on cancer cells, which helps to slow or stop the growth of the cancer.","indications":["ES-SCLC with disease progression"],"catalyst":""},{"name":"Imlygic","genericName":"TALIMOGENE LAHERPAREPVEC","slug":"talimogene-laherparepvec","phase":"marketed","mechanism":"Imlygic is a genetically modified virus that selectively infects and kills cancer cells, stimulating an anti-tumor immune response.","indications":["Local treatment of unresectable melanoma lesions"],"catalyst":""},{"name":"Irinotecan Based Chemotherapy","genericName":"Irinotecan Based Chemotherapy","slug":"irinotecan-based-chemotherapy","phase":"phase_3","mechanism":"Irinotecan is a topoisomerase I inhibitor that prevents DNA religation during replication, leading to DNA damage and cancer cell death.","indications":["Metastatic colorectal cancer","Small cell lung cancer","Ovarian cancer","Gastric cancer"],"catalyst":""},{"name":"KANJINTI","genericName":"TRASTUZUMAB-ANNS","slug":"trastuzumab-anns","phase":"marketed","mechanism":"","indications":["Adjuvant Breast Cancer","Metastatic Breast Cancer - First Line","Metastatic Breast Cancer - Subsequent Therapy","Metastatic Gastric Cancer"],"catalyst":""},{"name":"Kineret® (Anakinra)","genericName":"Kineret® (Anakinra)","slug":"kineret-anakinra","phase":"marketed","mechanism":"Anakinra is a recombinant interleukin-1 receptor antagonist that blocks IL-1 signaling to reduce inflammation.","indications":["Rheumatoid arthritis","Neonatal-onset multisystem inflammatory disease (NOMID)","Deficiency of interleukin-1 receptor antagonist (DIRA)"],"catalyst":""},{"name":"Low-intensity chemotherapy regimen","genericName":"Low-intensity chemotherapy regimen","slug":"low-intensity-chemotherapy-regimen","phase":"phase_3","mechanism":"Low-intensity chemotherapy regimens use reduced doses of cytotoxic agents to kill rapidly dividing cancer cells while minimizing toxicity in vulnerable patient populations.","indications":["Hematologic malignancies in elderly or frail patients","Acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy"],"catalyst":""},{"name":"MR prednisone","genericName":"MR prednisone","slug":"mr-prednisone","phase":"phase_3","mechanism":"MR prednisone is a modified-release formulation of the corticosteroid prednisone that provides delayed and prolonged release to optimize anti-inflammatory and immunosuppressive effects.","indications":["Rheumatoid arthritis","Other inflammatory and autoimmune conditions (specific indication in Phase 3 trial not publicly confirmed)"],"catalyst":""},{"name":"Medical Standard of Care for ITP","genericName":"Medical Standard of Care for ITP","slug":"medical-standard-of-care-for-itp","phase":"phase_3","mechanism":"This represents the established standard treatment approach for immune thrombocytopenia (ITP), which typically aims to increase platelet counts through immune modulation or platelet production stimulation.","indications":["Immune thrombocytopenia (ITP)"],"catalyst":""},{"name":"NaPBA","genericName":"NaPBA","slug":"napba","phase":"marketed","mechanism":"NaPBA (sodium phenylbutyrate) reduces ammonia levels by providing an alternative pathway for nitrogen excretion through conjugation with glutamine.","indications":["Urea cycle disorders (hyperammonemia management)","Acute hyperammonemic encephalopathy"],"catalyst":""},{"name":"Neulasta","genericName":"PEGFILGRASTIM","slug":"pegfilgrastim","phase":"marketed","mechanism":"Neulasta stimulates the production of white blood cells by binding to their receptors.","indications":["Allogeneic peripheral blood stem cell transplant","Chemotherapy-induced neutropenia"],"catalyst":""},{"name":"Neulasta® (pegfilgrastim)","genericName":"Neulasta® (pegfilgrastim)","slug":"neulasta-pegfilgrastim","phase":"marketed","mechanism":"Pegfilgrastim stimulates the proliferation and differentiation of neutrophil progenitor cells in bone marrow to increase circulating neutrophil counts.","indications":["Chemotherapy-induced neutropenia (CIN) in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy","Severe chronic neutropenia (SCN)","Mobilization of peripheral blood progenitor cells for autologous transplantation"],"catalyst":""},{"name":"New Formulation Etanercept","genericName":"New Formulation Etanercept","slug":"new-formulation-etanercept","phase":"phase_3","mechanism":"New Formulation Etanercept blocks the action of tumor necrosis factor-alpha (TNF-α), reducing inflammation.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Plaque psoriasis"],"catalyst":""},{"name":"Non-steroidal aromatase inhibitor therapy","genericName":"Non-steroidal aromatase inhibitor therapy","slug":"non-steroidal-aromatase-inhibitor-therapy","phase":"phase_3","mechanism":"A non-steroidal aromatase inhibitor blocks the enzyme aromatase to reduce estrogen production in postmenopausal women with hormone receptor-positive breast cancer.","indications":["Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant or metastatic setting)"],"catalyst":""},{"name":"Ocrelizumab (EU)","genericName":"Ocrelizumab (EU)","slug":"ocrelizumab-eu","phase":"phase_3","mechanism":"Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells.","indications":["Relapsing forms of multiple sclerosis","Primary progressive multiple sclerosis","Non-Hodgkin's lymphoma"],"catalyst":""},{"name":"Oxaliplatin Based Chemotherapy","genericName":"Oxaliplatin Based Chemotherapy","slug":"oxaliplatin-based-chemotherapy","phase":"phase_3","mechanism":"Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells.","indications":["Metastatic colorectal cancer (in combination with fluorouracil and leucovorin)","Adjuvant treatment of stage III colon cancer (in combination with fluorouracil and leucovorin)","Advanced ovarian cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"PAVBLU","genericName":"AFLIBERCEPT-AYYH","slug":"aflibercept-ayyh","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Pegloticase with MTX","genericName":"Pegloticase with MTX","slug":"pegloticase-with-mtx","phase":"marketed","mechanism":"Pegloticase is a pegylated uricase enzyme that breaks down uric acid into allantoin, while methotrexate (MTX) is added to reduce anti-drug antibody formation and improve tolerability.","indications":["Chronic gout refractory to conventional urate-lowering therapy"],"catalyst":""},{"name":"Pembrolizumab (EU)","genericName":"Pembrolizumab (EU)","slug":"pembrolizumab-eu","phase":"phase_3","mechanism":"Pembrolizumab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.","indications":["Metastatic melanoma","Non-small cell lung cancer (NSCLC)","Head and neck squamous cell carcinoma","Hodgkin lymphoma","Urothelial carcinoma"],"catalyst":""},{"name":"Pembrolizumab (US)","genericName":"Pembrolizumab (US)","slug":"pembrolizumab-us","phase":"phase_3","mechanism":"Pembrolizumab is a monoclonal antibody that blocks the PD-1 receptor, preventing cancer cells from evading the immune system.","indications":[],"catalyst":""},{"name":"Placebo for etanercept subcutaneous injection","genericName":"Placebo for etanercept subcutaneous injection","slug":"placebo-for-etanercept-subcutaneous-injection","phase":"phase_3","mechanism":"This drug is a placebo for etanercept subcutaneous injection, meaning it has no active therapeutic effect.","indications":["Treatment of moderate to severe rheumatoid arthritis"],"catalyst":""},{"name":"Placebo for methotrexate","genericName":"Placebo for methotrexate","slug":"placebo-for-methotrexate","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in Phase 3 clinical trial for methotrexate"],"catalyst":""},{"name":"Placebo for risendronate","genericName":"Placebo for risendronate","slug":"placebo-for-risendronate","phase":"phase_3","mechanism":"This is a placebo, meaning it has no active pharmacological effect.","indications":["Treatment of osteoporosis"],"catalyst":""},{"name":"Placebo to Alendronate","genericName":"Placebo to Alendronate","slug":"placebo-to-alendronate","phase":"phase_3","mechanism":"Alendronate works by inhibiting osteoclast-mediated bone resorption.","indications":["Treatment of osteoporosis in postmenopausal women and men","Treatment of glucocorticoid-induced osteoporosis"],"catalyst":""},{"name":"Placebo to Atorvastatin","genericName":"Placebo to Atorvastatin","slug":"placebo-to-atorvastatin","phase":"phase_3","mechanism":"This is a Phase 3 trial comparing placebo to atorvastatin, a statin that lowers cholesterol by inhibiting HMG-CoA reductase.","indications":["Hypercholesterolemia and cardiovascular risk reduction (specific indication dependent on Phase 3 trial design)"],"catalyst":""},{"name":"Placebo to Denosumab","genericName":"Placebo to Denosumab","slug":"placebo-to-denosumab","phase":"marketed","mechanism":"Denosumab is a monoclonal antibody that binds to RANKL (receptor activator of nuclear factor kappa-B ligand) and prevents bone resorption by inhibiting osteoclast formation and activation.","indications":["Postmenopausal osteoporosis in women at high risk of fracture","Bone loss in men receiving androgen deprivation therapy for prostate cancer","Bone loss in women receiving aromatase inhibitor therapy for breast cancer","Giant cell tumor of bone","Prevention of skeletal-related events in patients with bone metastases from solid tumors"],"catalyst":""},{"name":"Placebo to Evolocumab","genericName":"Placebo to Evolocumab","slug":"placebo-to-evolocumab","phase":"phase_3","mechanism":"Evolocumab works by binding to PCSK9, a protein that regulates cholesterol levels in the blood, thereby increasing the levels of HDL and reducing the levels of LDL.","indications":["Hypercholesterolemia","Heterozygous familial hypercholesterolemia"],"catalyst":""},{"name":"Placebo to Ezetimibe","genericName":"Placebo to Ezetimibe","slug":"placebo-to-ezetimibe","phase":"phase_3","mechanism":"Ezetimibe inhibits cholesterol absorption in the small intestine by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter.","indications":["Hypercholesterolemia (primary and secondary prevention of cardiovascular disease)","Adjunctive therapy to statins for LDL cholesterol reduction"],"catalyst":""},{"name":"Placebo to Methotrexate","genericName":"Placebo to Methotrexate","slug":"placebo-to-methotrexate","phase":"phase_3","mechanism":"Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and reducing DNA synthesis and cell proliferation.","indications":["Rheumatoid arthritis","Various malignancies (acute leukemia, lymphoma, breast cancer)","Psoriasis","Inflammatory bowel disease"],"catalyst":""},{"name":"Placebo to Romosozumab","genericName":"Placebo to Romosozumab","slug":"placebo-to-romosozumab","phase":"phase_3","mechanism":"Romosozumab is a monoclonal antibody that inhibits sclerostin, a negative regulator of bone formation, thereby increasing bone mineral density and reducing fracture risk.","indications":["Postmenopausal osteoporosis in women at high risk of fracture","Osteoporosis in men at high risk of fracture"],"catalyst":""},{"name":"Placebo to zoledronic acid","genericName":"Placebo to zoledronic acid","slug":"placebo-to-zoledronic-acid","phase":"marketed","mechanism":"Zoledronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.","indications":["Hypercalcemia of malignancy","Multiple myeloma with bone disease","Bone metastases from solid tumors","Osteoporosis prevention and treatment"],"catalyst":""},{"name":"Placebo-Apremilast","genericName":"Placebo-Apremilast","slug":"placebo-apremilast","phase":"marketed","mechanism":"Apremilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Plaque psoriasis","Psoriatic arthritis","Ankylosing spondylitis","Behçet's disease-associated oral ulcers"],"catalyst":""},{"name":"RIABNI","genericName":"RITUXIMAB-ARRX","slug":"rituximab-arrx","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"RP103","genericName":"RP103","slug":"rp103","phase":"phase_3","mechanism":"RP103 is a monoclonal antibody targeting PCSK9.","indications":["Hypercholesterolemia"],"catalyst":""},{"name":"Rituximab (EU)","genericName":"Rituximab (EU)","slug":"rituximab-eu","phase":"phase_3","mechanism":"Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.","indications":["Non-Hodgkin's lymphoma","Chronic lymphocytic leukemia"],"catalyst":""},{"name":"Rituximab (US)","genericName":"Rituximab (US)","slug":"rituximab-us","phase":"phase_3","mechanism":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.","indications":["Non-Hodgkin's lymphoma (B-cell)","Chronic lymphocytic leukemia (CLL)","Rheumatoid arthritis","Granulomatosis with polyangiitis (GPA)","Microscopic polyangiitis (MPA)"],"catalyst":""},{"name":"Romozosumab","genericName":"Romozosumab","slug":"romozosumab","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Routine Lipid Management","genericName":"Routine Lipid Management","slug":"routine-lipid-management","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sensipar","genericName":"CINACALCET","slug":"cinacalcet","phase":"marketed","mechanism":"Sensipar works by activating the calcium-sensing receptor, which helps regulate calcium levels in the blood.","indications":["Hypercalcemia due to Primary Hyperparathyroidism","Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis","Parathyroid Carcinoma with Hypercalcemia"],"catalyst":""},{"name":"Sensipar®","genericName":"Sensipar®","slug":"sensipar","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Standard Gout Flare Prophylaxis","genericName":"Standard Gout Flare Prophylaxis","slug":"standard-gout-flare-prophylaxis","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TEPEZZA","genericName":"TEPEZZA","slug":"tepezza","phase":"marketed","mechanism":"TEPEZZA is a monoclonal antibody that blocks the insulin-like growth factor-1 receptor (IGF-1R) to reduce inflammation and tissue remodeling in thyroid eye disease.","indications":["Moderate-to-severe thyroid eye disease (TED)"],"catalyst":""},{"name":"Topical treatments or phototherapy","genericName":"Topical treatments or phototherapy","slug":"topical-treatments-or-phototherapy","phase":"phase_3","mechanism":"Phototherapy uses specific wavelengths of light to target and treat skin conditions.","indications":["Psoriasis","Vitiligo"],"catalyst":""},{"name":"Traditional Vitamin D Therapy","genericName":"Traditional Vitamin D Therapy","slug":"traditional-vitamin-d-therapy","phase":"marketed","mechanism":"Vitamin D supplementation increases serum 25-hydroxyvitamin D levels to support calcium homeostasis, bone mineralization, and immune function.","indications":["Vitamin D deficiency","Osteoporosis prevention and treatment","Hypoparathyroidism"],"catalyst":""},{"name":"Trifluridine and Tipiracil","genericName":"Trifluridine and Tipiracil","slug":"trifluridine-and-tipiracil","phase":"marketed","mechanism":"Trifluridine is a nucleoside analog that inhibits thymidylate synthase and gets incorporated into DNA to damage cancer cells, while tipiracil is a thymidine phosphorylase inhibitor that enhances trifluridine bioavailability.","indications":["Metastatic colorectal cancer (previously treated)","Metastatic gastric cancer (previously treated)"],"catalyst":""},{"name":"UPLIZNA","genericName":"UPLIZNA","slug":"uplizna","phase":"marketed","mechanism":"UPLIZNA is a neonatal Fc receptor (FcRn) antagonist that blocks the recycling and extends the half-life of pathogenic immunoglobulins, leading to their increased clearance from circulation.","indications":["Generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) antibody positive"],"catalyst":""},{"name":"VIMOVO 250/20","genericName":"VIMOVO 250/20","slug":"vimovo-250-20","phase":"marketed","mechanism":"VIMOVO combines naproxen (an NSAID) with esomeprazole (a proton pump inhibitor) to reduce pain and inflammation while protecting the stomach from NSAID-induced ulcers.","indications":["Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk for NSAID-induced gastric ulcers"],"catalyst":""},{"name":"VIMOVO 375/20","genericName":"VIMOVO 375/20","slug":"vimovo-375-20","phase":"marketed","mechanism":"VIMOVO combines naproxen (an NSAID) with esomeprazole (a proton pump inhibitor) to reduce pain and inflammation while protecting the stomach from NSAID-induced ulcers.","indications":["Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk for NSAID-induced gastric ulcers"],"catalyst":""},{"name":"VIMOVO 500/20","genericName":"VIMOVO 500/20","slug":"vimovo-500-20","phase":"marketed","mechanism":"VIMOVO combines naproxen (an NSAID) with esomeprazole (a proton pump inhibitor) to reduce pain and inflammation while protecting the stomach from NSAID-induced ulcers.","indications":["Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk for NSAID-induced gastric ulcers"],"catalyst":""},{"name":"Vincrisitne","genericName":"Vincrisitne","slug":"vincrisitne","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"WEZLANA","genericName":"USTEKINUMAB-AUUB","slug":"ustekinumab-auub","phase":"marketed","mechanism":"","indications":["Moderate to Severe Plaque Psoriasis","Active Psoriatic Arthritis","Moderately to Severely Active Crohn's Disease","Moderately to Severely Active Ulcerative Colitis"],"catalyst":""},{"name":"Xaluritamig","genericName":"Xaluritamig","slug":"xaluritamig","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[14C]CCX168","genericName":"[14C]CCX168","slug":"14c-ccx168","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"bisphosphonate","genericName":"bisphosphonate","slug":"bisphosphonate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"darbepoetin alfa SF","genericName":"darbepoetin alfa SF","slug":"darbepoetin-alfa-sf","phase":"phase_3","mechanism":"Darbepoetin alfa SF stimulates erythropoiesis by binding to the erythropoietin receptor.","indications":["Treatment of anemia associated with chronic kidney disease"],"catalyst":""},{"name":"erenumab-aooe","genericName":"erenumab-aooe","slug":"erenumab-aooe","phase":"marketed","mechanism":"Erenumab is a monoclonal antibody that binds to and blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.","indications":["Migraine prevention in adults","Chronic migraine prevention"],"catalyst":""},{"name":"gout flare prophylaxis regimen","genericName":"gout flare prophylaxis regimen","slug":"gout-flare-prophylaxis-regimen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"interferon γ-1b","genericName":"interferon γ-1b","slug":"interferon-1b","phase":"phase_3","mechanism":"Interferon γ-1b enhances immune responses by activating macrophages and natural killer cells, and it also has antiviral properties.","indications":["Chronic granulomatous disease (CGD)","Severe, malignant osteopetrosis"],"catalyst":""},{"name":"rHuEPO","genericName":"rHuEPO","slug":"rhuepo","phase":"marketed","mechanism":"rHuEPO (recombinant human erythropoietin) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production.","indications":["Anemia associated with chronic kidney disease","Anemia in patients with cancer receiving chemotherapy","Anemia in HIV-infected patients receiving zidovudine therapy","Perioperative anemia in patients undergoing elective surgery"],"catalyst":""},{"name":"romosozumab HCP administration with PFS","genericName":"romosozumab HCP administration with PFS","slug":"romosozumab-hcp-administration-with-pfs","phase":"phase_3","mechanism":"Romosozumab is a monoclonal antibody that targets sclerostin, a protein that inhibits bone formation.","indications":["Treatment of osteoporosis in postmenopausal women at high risk of fracture"],"catalyst":""}],"recentEvents":[{"date":"2024-02-01","type":"earnings","headline":"Amgen Reports Fourth-Quarter and Full-Year 2023 Financial Results","summary":"Amgen reported fourth-quarter and full-year 2023 financial results, with revenue of $6.9 billion and $26.6 billion, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Amgen and BeiGene Announce Collaboration to Develop and Commercialize Bispecific Antibody Therapies","summary":"Amgen and BeiGene announced a collaboration to develop and commercialize bispecific antibody therapies for various cancer indications.","drugName":"","sentiment":"positive"},{"date":"2023-09-15","type":"regulatory","headline":"FDA Approves Amgen's Lumakras for KRAS G12C-Mutated NSCLC","summary":"The FDA approved Amgen's Lumakras (sotorasib) for the treatment of adult patients with KRAS G12C-mutated non-small cell lung cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQcHFQNlIybFNDQXA1RTJwZXlCbUE0dEd5YTUyQ0FORlF2ZXdxemlXQ1hxeTVZTzREbGZlRWtXU2p4VEs0Q2UtdXo0SkRmN2FLeFk4M1JKYVUtSUc0TEFQSGxWVFdiS2JDLUNpeW9EbnhqOHVwTDEtSjdsSm5SZ0M3Z2lUVHFVdGlwOGloS3pyOTZWZzJNQUZF?oc=5","date":"2026-04-02","type":"pipeline","source":"Yahoo Finance","summary":"Is Amgen Inc. (AMGN) One of the Best Pharma Stocks to Invest in Now? - Yahoo Finance","headline":"Is Amgen Inc. (AMGN) One of the Best Pharma Stocks to Invest in Now?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQY0E5X211X1l2dTkzQjVuRVlmLWl0aG1JSG5hd0VjV0dvbUlOM05VUnhMd2ozaVNRNHdNdlY5UzlKN29zdVdKNHZNcVJZZjlXS3VOMWdZUjBjbU84b3FueHpxbUdaS1hjSnlKV2xnOXc0bm1BeWJKbDNMLUQ2MHNjaEVHbWt1R19LbWdjdGpfUVdWRVg2MnRKUlVhbU5BcTZsWUlqenUyQW81eTJSdjktQzJtZVJRbXVuNXpPUHd5Uk5CaFk0T3p5dFUyM1FmWW40OXc?oc=5","date":"2026-03-11","type":"pipeline","source":"Trefis","summary":"Between Amgen and Vertex Pharmaceuticals, Which Stock Looks Set to Break Out? - Trefis","headline":"Between Amgen and Vertex Pharmaceuticals, Which Stock Looks Set to Break Out?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5aT04yclFCbmtmazd6NzR3UXhPcklOZ1dkQkF0ZlNGWmMyb2VoRG9CQ0NIS3VoeWpwdkVmako5aDVkcDdSSzJ6eUd3cWY1QWJoNGMtUTFyelJSbFNYUXpZbk5ZbkNsX1FkdmUtb1J4N3k1TFBkTVhLNE1IZThEeDA?oc=5","date":"2026-01-29","type":"pipeline","source":"Yahoo Finance","summary":"UBS Raises Amgen (AMGN) Target as Pharma and Biotech Setup Improves - Yahoo Finance","headline":"UBS Raises Amgen (AMGN) Target as Pharma and Biotech Setup Improves","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNYll1RzNmdkl3Xzd4Q19rTkF2YVIyeEthMWw2TlVNZjdIRlFETkE2Mm1DenFUN0pPaUtZWE1kR1ZTTmJWX1FmQ3hLd25xOUNZMTlRNlBsZmtpTm92aERKbTFXeURucTRrSHpYNm81QnRJdUhRZWRhNXRWLV85NDNwUk1XRHlvUDlDRC1fR0VTU3lXbDU4MnhiQjVua1lUam1ucG9yUTlvZjRlb2thTjNFanB4UVI5UFh4UU1BY2hxSnl5REpUbWtuMFo4VXhvX1VWS0c3aDlpSE9XSTd0?oc=5","date":"2025-12-22","type":"deal","source":"TechStock²","summary":"Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025) - TechStock²","headline":"Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxQNnBXOFo3SWI4dF9scXZMVUE2OUV2X2JCejBqMGQxcDgxTFlPcXJyOXhhcjRDMnplUFlLSFNKMDduS2ZhU0ZaenVhNm11VE5RLUMzWlNzQUJad1ZkZ0NCcEFTUEU4aE1qWXN0RDdzYkc0TVpIcFIyRlFQUDIzS0F6SExSMXFtZ0tWaExMaXozSzlrR3pUdHowX0hYZWJ3dEtUTlFBR0pzZHRqdGVhQ2RWd3pjWjBpNnhiWVZQQ3EyMzViVWJLbVYyWVk5UUFkRXhCejRoNi1peEtlTExZUjdNdFVUbTJfYzJGcWxmWTViTllUckVoY2hteHNLaGZNX1NTU1E?oc=5","date":"2025-11-18","type":"pipeline","source":"Benzinga","summary":"Tech Stocks Drop, Pharma Gains As Sector Rotation Picks Up: - Amgen (NASDAQ:AMGN) - Benzinga","headline":"Tech Stocks Drop, Pharma Gains As Sector Rotation Picks Up: - Amgen (NASDAQ:AMGN)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-06","type":"earnings","source":"simplywall.st","summary":"Amgen (AMGN): Earnings Surge 111% Challenges Bearish Views on Profitability Turnaround - simplywall.st","headline":"Amgen (AMGN): Earnings Surge 111% Challenges Bearish Views on Profitability Turnaround","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPLVQwNVBydzkwa1R0N09PUXprcW9IWV85MWQxNjVFSTgwZ0FXVVQyb3FuQ3lyTkpPa18wQmRBTEF3R0xBTFEzVFJDeU85ZmJqZmpmdHQ3M1dXQXMzdmhrY2pxWER2TWpac3B1WkkxNG1aQlZIcjdHNEFOVnZzU2wtRHN1ZzlrNlA4azlfbWxYSXh4OWpBRFNXZUdCYkJLRXdRQmVhQjBGcEJxSGFpQzRvcFVoNU4?oc=5","date":"2025-10-06","type":"pipeline","source":"TipRanks","summary":"Amgen Stock (AMGN) Falls as It Cuts 60% Off Cholesterol Drug Price, Heeding Trump’s Clamor - TipRanks","headline":"Amgen Stock (AMGN) Falls as It Cuts 60% Off Cholesterol Drug Price, Heeding Trump’s Clamor","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-30","type":"regulatory","source":"simplywall.st","summary":"A Fresh Look at Amgen (AMGN) Valuation After FDA Expands Repatha’s Market Opportunity - simplywall.st","headline":"A Fresh Look at Amgen (AMGN) Valuation After FDA Expands Repatha’s Market Opportunity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQRVY0cUNrMzFCRHl2MU5lMFliV1NhZThyWkhCdlpha0x4aXk0YTRoaUgzTGtudnphWDdJaW5VUzVDZ2Npb1RNaFl6SjZuclBUNk43WE9ZMGFWV29VQllDRmQtT0pnazY4MGN3MVNtRTk4a0tOeWEzdW5sOVl6ZUxzT3VobXhLQnFlSHJnWTRVZ1p5M0I0ejhNRXZ4aVVtRTh0OUtETXdHSzAzVFcwYUlRRTl2MkxWeEpGN201NQ?oc=5","date":"2025-08-25","type":"pipeline","source":"Reuters","summary":"Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug - Reuters","headline":"Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPWGMxdENKZ2pVZF9LTUNJZ0prU2FRN3VQVGJLM1JldkdQdWJyTDY2QkMtMTFCS0dsMDhfemdFR2hEQ3cyaFdQRDFkdU5lT0dMUXdQR0dvMEhGYktDSEZfV3k0LTQzTzJRVjVqUmk5VlB4dWVhV05UR0lvQW1WRFRNdEVCTEtESnNJZE94aHNDSzJlc2E5eUE?oc=5","date":"2025-07-29","type":"earnings","source":"CMC Markets","summary":"Biotech Earnings Preview: REGN, MRNA, BNTX, VRTX and AMGN - CMC Markets","headline":"Biotech Earnings Preview: REGN, MRNA, BNTX, VRTX and AMGN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOS3ZkTm53Q0hRYWFrbTdoR2pEc3djaVlDWG9hQjIwMGlHc0piWWhLWGFMd1VGTkJOT1FwVGJmd3F4S29YQlhEX0lLcTFLYk1KbE15QTNwMGh6X1k1N2NqYURWaWdEOU9jQWFZcHIzNDFmXzlidDY0cjhmY2tCczN6dXE1TGtsS3JYTXBHd0VDc3A4N2h6N2YwNkh2T3hWWm4y?oc=5","date":"2025-07-23","type":"deal","source":"Zacks Investment Research","summary":"Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy? - Zacks Investment Research","headline":"Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE5ZTFhiVzlSdG1uVVhSN0d6a0FIUXVhOTVndjQyOGcwdURrVGFUQVpCQi1FRHZIT2dxWXFtc1VlcWFqYWxGREpfeXhka0VHUVRkUjd4Uk92MFFkWWxnX2V3dHZ1b2g3d1RZTmI4T0tPeW1odHJQMjdV?oc=5","date":"2025-04-10","type":"pipeline","source":"Barron's","summary":"Amgen Is Getting Into the Obesity Drug Business. The Stock Could Become the Next Winner. - Barron's","headline":"Amgen Is Getting Into the Obesity Drug Business. The Stock Could Become the Next Winner. - Barron's","sentiment":"neutral"}],"patents":[{"drugName":"Enbrel","drugSlug":"etanercept","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":4500000000},{"drugName":"Otezla","drugSlug":"apremilast","patentNumber":"7427638*PED","type":"Compound","expiryDate":"2028-08-16","territory":"US","annualRevenue":2100000000,"genericFilings":[]},{"drugName":"Erenumab","drugSlug":"erenumab-aooe","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"Otezla","drugSlug":"apremilast","patentNumber":"9872854","type":"Method of Use","expiryDate":"2034-05-29","territory":"US","annualRevenue":2100000000,"genericFilings":[]},{"drugName":"Otezla","drugSlug":"apremilast","patentNumber":"9872854*PED","type":"Compound","expiryDate":"2034-11-29","territory":"US","annualRevenue":2100000000,"genericFilings":[]},{"drugName":"Otezla","drugSlug":"apremilast","patentNumber":"10092541*PED","type":"Compound","expiryDate":"2034-11-29","territory":"US","annualRevenue":2100000000,"genericFilings":[]}],"drugCount":188,"phaseCounts":{"marketed":66,"phase_1":38,"phase_3":66,"phase_2":18},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Gilead Sciences","Biogen","Regeneron Pharmaceuticals"],"therapeuticFocus":["Oncology","Inflammation"],"financials":{"source":"sec_edgar","revenue":25424000000,"revenuePeriod":"2020-12-31","revenueHistory":[{"value":25424000000,"period":"2020-12-31"},{"value":23362000000,"period":"2019-12-31"},{"value":23362000000,"period":"2019-12-31"},{"value":23747000000,"period":"2018-12-31"},{"value":23747000000,"period":"2018-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":7711000000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":90586000000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":346.57,"previousClose":340,"fiftyTwoWeekHigh":391.29,"fiftyTwoWeekLow":261.43,"fiftyTwoWeekRange":"261.43 - 391.29","fiftyDayAverage":363.05,"twoHundredDayAverage":319.48,"beta":0.47,"enterpriseValue":229589008384,"forwardPE":14.9,"priceToBook":21.57,"priceToSales":5.08,"enterpriseToRevenue":6.25,"enterpriseToEbitda":13.82,"pegRatio":2.33,"ebitda":16616999936,"ebitdaMargin":45.2,"freeCashflow":7501875200,"operatingCashflow":9957999616,"totalDebt":55435001856,"debtToEquity":640.3,"currentRatio":1.14,"returnOnAssets":7.9,"returnOnEquity":106.1,"analystRating":"2.5 - Buy","recommendationKey":"buy","numberOfAnalysts":29,"targetMeanPrice":350.76,"targetHighPrice":432,"targetLowPrice":200,"dividendRate":10.08,"payoutRatio":0.67,"fiveYearAvgDividendYield":3.06,"exDividendDate":1778803200,"insiderHeldPercent":0.2,"institutionHeldPercent":85.3,"sharesOutstanding":539067675,"floatShares":537617583,"sharesShort":14323209,"shortRatio":6.07,"shortPercentOfFloat":2.7,"epsTrailing":14.25,"epsForward":23.28,"revenuePerShare":68.31,"bookValue":16.07,"officers":[{"age":62,"name":"Mr. Robert A. Bradway","title":"Chairman & CEO"},{"age":66,"name":"Mr. Peter H. Griffith","title":"Executive VP & CFO"},{"age":62,"name":"Dr. David M. Reese M.D.","title":"Executive VP & CTO"},{"age":58,"name":"Mr. Murdo  Gordon","title":"Executive Vice President of Global Commercial Operations"},{"age":53,"name":"Dr. James E. Bradner M.D.","title":"Executive Vice President of Research & Development"},{"age":57,"name":"Mr. Esteban  Santos","title":"Executive Vice President of Operations"},{"age":50,"name":"Mr. Matthew C. Busch","title":"Chief Accounting Officer & VP of Finance"},{"age":null,"name":"Mr. Scott  Skellenger","title":"Senior VP & Chief Information Officer"}],"industry":"Drug Manufacturers - General","irWebsite":"http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-IRHome","website":"https://www.amgen.com","phone":"805 447 1000"}}